Blueprint Medicines: 2Q Earnings Snapshot

August 1, 2018

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Wednesday reported a loss of $27 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of 62 cents per share.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.31 per share.

The cancer drug developer posted revenue of $41.4 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $3.2 million.

Blueprint Medicines shares have fallen 21 percent since the beginning of the year. The stock has increased 14 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC

Update hourly